NASDAQ:SLDB Solid Biosciences (SLDB) Stock Price, News & Analysis $6.95 -0.11 (-1.56%) As of 11:14 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Solid Biosciences Stock (NASDAQ:SLDB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Solid Biosciences alerts:Sign Up Key Stats Today's Range$6.65▼$7.1150-Day Range$6.85▼$10.4252-Week Range$3.79▼$11.45Volume314,631 shsAverage Volume1.36 million shsMarket Capitalization$745.21 millionP/E RatioN/ADividend YieldN/APrice Target$18.69Consensus RatingModerate Buy Company Overview Solid Biosciences Inc. is a biotechnology company focused on developing genetic medicines for patients with rare diseases. The company’s research platform is centered on adeno-associated virus (AAV) gene therapy and other genetic medicine technologies intended to address the underlying causes of disease. Solid Biosciences’ lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a severe inherited neuromuscular disorder. The company is also developing additional programs for rare cardiac and neuromuscular conditions, including SGT-501 for BAG3-associated dilated cardiomyopathy. These candidates remain in clinical or preclinical development, and the company does not have an approved commercial product. Founded in 2013, Solid Biosciences is headquartered in the United States and conducts research and clinical development activities through U.S.-based operations and collaborations. The company is led by Chief Executive Officer Bo Cumbo. Its programs are designed for patients with serious rare diseases in the United States and potentially other markets, subject to clinical and regulatory outcomes.AI Generated. May Contain Errors. Read More Solid Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreSLDB MarketRank™: Solid Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 616th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSolid Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSolid Biosciences has a consensus price target of $18.69, representing about 178.9% upside from its current price of $6.70.Amount of Analyst CoverageSolid Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Solid Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Solid Biosciences are expected to decrease in the coming year, from ($1.66) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Solid Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.39% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 19.63, which indicates bearish sentiment.Change versus previous monthShort interest in Solid Biosciences has recently increased by 4.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.19 News SentimentSolid Biosciences has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Solid Biosciences this week, compared to 4 articles on an average week.MarketBeat Follows5 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.66% of the stock of Solid Biosciences is held by insiders.Percentage Held by Institutions81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Solid Biosciences' insider trading history. Receive SLDB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLDB Stock News HeadlinesSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2026 | globenewswire.comSolid Biosciences: A Funded Challenge To Duchenne Gene Therapy's LimitationsSeptember 25, 2026 | seekingalpha.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 6 at 1:00 AM | Profits Run (Ad)RBC Capital initiates coverage of Solid Biosciences at outperformSeptember 17, 2026 | msn.comSolid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC SaysSeptember 16, 2026 | finance.yahoo.comSolid Biosciences wins new Outperform at RBC on DMD opportunitySeptember 16, 2026 | seekingalpha.comSolid Biosciences (SLDB) Gets a Buy from CitiSeptember 12, 2026 | theglobeandmail.comSolid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comSee More Headlines SLDB Stock Analysis - Frequently Asked Questions How have SLDB shares performed this year? Solid Biosciences' stock was trading at $5.64 at the beginning of 2026. Since then, SLDB shares have increased by 18.8% and is now trading at $6.7020. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc. (NASDAQ:SLDB) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. When did Solid Biosciences' stock split? Solid Biosciences shares reverse split on Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Solid Biosciences IPO? Solid Biosciences (SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. How do I buy shares of Solid Biosciences? Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/06/2026Today10/06/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SLDB's financial health is in the Green zone, according to TradeSmith. SLDB has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SLDB CIK1707502 Webwww.solidbio.com Phone(617) 337-4680FaxN/AEmployees121Year Founded2013Price Target and Rating Average Price Target for Solid Biosciences$18.69 High Price Target$26.00 Low Price Target$9.00 Potential Upside/Downside+177.1%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$174.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.35% Return on Assets-60.58% Debt Debt-to-Equity RatioN/A Current Ratio13.82 Quick Ratio13.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book2.96Miscellaneous Outstanding Shares107,225,000Free Float104,373,000Market Cap$723.34 million OptionableOptionable Beta2.47 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:SLDB) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLDB Stock Alerts